213 related articles for article (PubMed ID: 10479408)
1. Interleukin 10 mitigates the development of the zymosan-induced multiple organ dysfunction syndrome in mice.
Jansen MJ; Hendriks T; de Man BM; van der Meer JW; Goris RJ
Cytokine; 1999 Sep; 11(9):713-21. PubMed ID: 10479408
[TBL] [Abstract][Full Text] [Related]
2. A monoclonal antibody against tumour necrosis factor-alpha improves survival in experimental multiple organ dysfunction syndrome.
Jansen MJ; Hendriks T; Hermsen R; Van der Meer JW; Goris RJ
Cytokine; 1998 Nov; 10(11):904-10. PubMed ID: 9878128
[TBL] [Abstract][Full Text] [Related]
3. Absence of endogenous interleukin-10 enhanced organ dysfunction and mortality associated to zymosan-induced multiple organ dysfunction syndrome.
Malleo G; Mazzon E; Genovese T; Di Paola R; Caminiti R; Esposito E; Bramanti P; Cuzzocrea S
Cytokine; 2008 Feb; 41(2):136-43. PubMed ID: 18160304
[TBL] [Abstract][Full Text] [Related]
4. Chlorpromazine down-regulates tumor necrosis factor-alpha and attenuates experimental multiple organ dysfunction syndrome in mice.
Jansen MJ; Hendriks T; Knapen MF; van Kempen LC; van der Meer JW; Goris RJ
Crit Care Med; 1998 Jul; 26(7):1244-50. PubMed ID: 9671376
[TBL] [Abstract][Full Text] [Related]
5. Etanercept reduces acute tissue injury and mortality associated to zymosan-induced multiple organ dysfunction syndrome.
Malleo G; Mazzon E; Genovese T; Di Paola R; Muià C; Caminiti R; Esposito E; Di Bella P; Cuzzocrea S
Shock; 2008 May; 29(5):560-71. PubMed ID: 17724436
[TBL] [Abstract][Full Text] [Related]
6. Treatment with Y-40138, a multiple cytokine production modulator, inhibits lipopolysaccharide- or tumour necrosis factor-alpha-induced production of pro-inflammatory cytokines and augments interleukin-10.
Fukuda T; Hisadome M; Komatsu H
J Pharm Pharmacol; 2005 Nov; 57(11):1461-6. PubMed ID: 16259779
[TBL] [Abstract][Full Text] [Related]
7. Role of interleukin-6 in a non-septic shock model induced by zymosan.
Cuzzocrea S; de Sarro G; Costantino G; Mazzon E; Laurà R; Ciriaco E; de Sarro A; Caputi AP
Eur Cytokine Netw; 1999 Jun; 10(2):191-203. PubMed ID: 10400825
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-10 reduces morbidity and mortality in murine multiple organ dysfunction syndrome (MODS).
Ferrer TJ; Webb JW; Wallace BH; Bridges CD; Palmer HE; Robertson RD; Cone JB
J Surg Res; 1998 Jul; 77(2):157-64. PubMed ID: 9733603
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-18 induces production of proinflammatory cytokines in mice: no intermediate role for the cytokines of the tumor necrosis factor family and interleukin-1beta.
Netea MG; Kullberg BJ; Verschueren I; Van Der Meer JW
Eur J Immunol; 2000 Oct; 30(10):3057-60. PubMed ID: 11069090
[TBL] [Abstract][Full Text] [Related]
10. The immunomodulatory effects of the herbicide propanil on murine macrophage interleukin-6 and tumor necrosis factor-alpha production.
Xie YC; Schafer R; Barnett JB
Toxicol Appl Pharmacol; 1997 Jul; 145(1):184-91. PubMed ID: 9221836
[TBL] [Abstract][Full Text] [Related]
11. Peritoneal mesothelial cells produce inflammatory related cytokines.
Yao V; Platell C; Hall JC
ANZ J Surg; 2004 Nov; 74(11):997-1002. PubMed ID: 15550091
[TBL] [Abstract][Full Text] [Related]
12. Inflammatory cytokines in an experimental model for the multiple organ dysfunction syndrome.
Jansen MJ; Hendriks T; Vogels MT; van der Meer JW; Goris RJ
Crit Care Med; 1996 Jul; 24(7):1196-202. PubMed ID: 8674335
[TBL] [Abstract][Full Text] [Related]
13. Multiple organ dysfunction syndrome: end organ and systemic inflammatory response in a mouse model of nonseptic origin.
Shayevitz JR; Miller C; Johnson KJ; Rodriguez JL
Shock; 1995 Dec; 4(6):389-96. PubMed ID: 8608394
[TBL] [Abstract][Full Text] [Related]
14. Absence of peroxisome proliferators-activated receptors (PPAR)alpha enhanced the multiple organ failure induced by zymosan.
Di Paola R; Esposito E; Mazzon E; Genovese T; Muià C; Crisafulli C; Malleo G; Sessa E; Meli R; Cuzzocrea S
Shock; 2006 Nov; 26(5):477-84. PubMed ID: 17047518
[TBL] [Abstract][Full Text] [Related]
15. R- and S-isomers of nonsteroidal anti-inflammatory drugs differentially regulate cytokine production.
Mascagni P; Sabbatini V; Biordi L; Martinotti S; Allegretti M; Marullo A; Caselli G; Bertini R
Eur Cytokine Netw; 2000 Jun; 11(2):185-92. PubMed ID: 10903797
[TBL] [Abstract][Full Text] [Related]
16. Glutamine treatment attenuates the development of organ injury induced by zymosan administration in mice.
Mondello S; Galuppo M; Mazzon E; Italiano D; Mondello P; Aloisi C; Cuzzocrea S
Eur J Pharmacol; 2011 May; 658(1):28-40. PubMed ID: 21349270
[TBL] [Abstract][Full Text] [Related]
17. Dose-dependent improvements in outcome with adenoviral expression of interleukin-10 in a murine model of multisystem organ failure.
McAuliffe PF; Murday ME; Efron PA; Scumpia PO; Ungaro R; Abouhamze A; Tannahill CL; Hutchins B; LaFace D; Moldawer LL
Gene Ther; 2006 Feb; 13(3):276-82. PubMed ID: 16251998
[TBL] [Abstract][Full Text] [Related]
18. Improved survival of TNF-deficient mice during the zymosan-induced multiple organ dysfunction syndrome.
Volman TJ; Hendriks T; Verhofstad AA; Kullberg BJ; Goris RJ
Shock; 2002 Jun; 17(6):468-72. PubMed ID: 12069182
[TBL] [Abstract][Full Text] [Related]
19. GITR gene deletion and GITR-FC soluble protein administration inhibit multiple organ failure induced by zymosan.
Galuppo M; Nocentini G; Mazzon E; Ronchetti S; Esposito E; Riccardi L; Di Paola R; Bruscoli S; Riccardi C; Cuzzocrea S
Shock; 2011 Sep; 36(3):263-71. PubMed ID: 21654556
[TBL] [Abstract][Full Text] [Related]
20. Increased expression of matrix metalloproteinases in the murine zymosan-induced multiple organ dysfunction syndrome.
Volman TJ; Goris RJ; Lomme RM; DeGroot J; Verhofstad AA; Hendriks T
J Pathol; 2004 Aug; 203(4):968-75. PubMed ID: 15259001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
